TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo
Open Access
- 3 August 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (15)
Abstract
TRAIL is a TNF family ligand that trimerizes TRAIL-R1 (DR4) or TRAIL-R2 (DR5) to induce apoptosis, necroptosis, and/or NF-κB activation in receptor-bearing cells. We previously identified TRAILshort as a splice variant of TRAIL that lacks cysteine 230, cannot trimerize, and acts as a dominant-negative ligand that blocks TRAIL-mediated apoptosis. TRAILshort is expressed on cell surfaces and within extracellular vesicles, enabling it to confer TRAIL resistance to both producing and bystander cells. In this study, we showed that elevated TRAILshort levels were associated with chronic viral infections, cancer, and autoimmune diseases, suggesting a link to impaired immune regulation. Using unbiased phosphoproteomics and mechanistic studies, we demonstrated that TRAILshort binding to DR5 recruited and activated the phosphatase Src homology region 2 domain–containing phosphatase 1 (SHP-1), leading to zeta-chain-associated protein kinase 70 (ZAP-70) dephosphorylation, disruption of ZAP-70–CD3ζ interactions, and impaired T cell receptor signaling, thereby reducing T cell activation, proliferation, and cytokine production in response to antigen or CD3/CD28 ligation. Genetic or pharmacologic SHP-1 inhibition reverses these effects. In humanized mouse models, TRAILshort promoted the persistence of transformed mouse embryonic fibroblasts (MEFs) and L428 and antagonized CD19-directed CAR T cell activity, revealing TRAILshort as an immunomodulator of T cell function with therapeutic implications, including blocking TRAILshort to restore T cell immunity or delivering TRAILshort to enforce tolerance. TRAILshort, a variant of TRAIL, suppresses T cell function and immune responses in cancer and infectious diseases, highlighting its potential as a therapeutic target.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI110173,AI83801,1UM1AI164562)
- NCI (U01CA271410,P30CA15083)
This publication has 78 references indexed in Scilit:
- Intrinsic immunosuppressive features of monocytes suppress CAR-T19 through IL-1 pathway modulation in mantle cell lymphomaMolecular Therapy Oncology, 2025
- Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human studyInvestigational New Drugs, 2022
- Frequent expression of PD‐L1 on circulating breast cancer cellsMolecular Oncology, 2015
- Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3Biochemical Pharmacology, 2012
- Overall survival and PD‐L1 expression in metastasized malignant melanomaCancer, 2010
- Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatmentJournal of Hepatology, 2008
- BAFF is elevated in serum of patients with Wegener's granulomatosisJournal of Autoimmunity, 2005
- Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5Immunity, 2000
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995
- Characterization of protein tyrosine phosphatase SH-PTP2. Study of phosphopeptide substrates and possible regulatory role of SH2 domains.Journal of Biological Chemistry, 1994